



Lazzaro responds to Pouwels et al.

Carlo Lazzaro¹

Received: 23 July 2021 / Accepted: 29 July 2021 / Published online: 5 August 2021

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Dear Sirs,

In their interesting review [1], Pouwels et al. quoted our article an Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients [2].

While we thank Pouwels et al. for their interest in our research, we are really surprised about their statement at page 488 “Lazzaro et al. was unclear about how treatment effectiveness has modeled [39].” [1]. Indeed (page 126), we clearly reported that “Transition probabilities among Markov model states were estimated via the Weibull distribution. The Weibull distribution was used to generalize progression-free survival (PFS) and OS, in order to extrapolate survival in the model beyond the follow-up of the abovementioned RCT that compared nab-paclitaxel versus conventional paclitaxel.¹¹” [2].

Therefore, what is unclear about our approach, as PFS and OS survival, measured in Life-Year Saved (LYS), were the effectiveness outcomes, to be translated into Quality-Adjusted Life Years for cost-utility analysis [3, 4].

In addition:

- (1) Table 1 (page 490): Pouwels et al. claimed that second line treatment was not mentioned in our paper [1]. However (page 126), we stated that “...in MBC patients as a second-line treatment whenever standard, anthracycline-containing therapy is not indicated.¹³” [2].
- (2) Table 2 (page 492): Pouwels et al. claimed that incremental LYS by Nab-paclitaxel vs. paclitaxel were not mentioned in our paper [1], whereas they were clearly reported (page 130) “...nab-paclitaxel... saves 0.265 life years more than conventional paclitaxel (1.439 versus 1.173).” [2].

While the role of review articles in health economics and related research fields is of paramount importance, the strength of their recommendations is obviously conditional on a careful description of the studies retrieved from the literature.

Author contributions Carlo Lazzaro drafted this Letter to the Editor.

Funding Not applicable.

Declarations

Conflict of interest Carlo Lazzaro has no conflicts of interest/competing interests with this Letter to the Editor. Outside this Letter to the Editor, in the past 3 years Carlo Lazzaro has received research grants, speaker or consultancy fees from AstraZeneca S.p.A., Boehringer Ingelheim Italia S.p.A., CSL Behring S.p.A., Ferring S.p.A., Ipsen S.p.A., Roche S.p.A., Sanofi S.p.A., Santen GmbH, Shire S.p.A., Sobi S.p.A.

References

1. Pouwels XGLV, Ramaekers BLT, Joore MA (2017) Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. *Breast Cancer Res Treat* 165(3):485–498
2. Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E (2013) An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. *Clinicoecon Outcomes Res* 5:125–135
3. Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE (eds) (2016) *Cost-effectiveness in health and medicine*, 2nd edn. Oxford University Press, New York
4. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) *Methods for the economic evaluation of health care programmes*, 4th edn. Oxford University Press, Oxford

✉ Carlo Lazzaro
carlo.lazzaro@tiscalinet.it

¹ Studio di Economia Sanitaria, Via Stefanardo da Vimercate, 19, 20128 Milan, Italy

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.